Back to News
Market Impact: 0.25
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial
Source: Nasdaq
Healthcare & Biotech
Azitra amended its ongoing Phase 1/2 trial of ATR04-484 to broaden eligibility to patients with rash associated with KRAS and MEK inhibitors and to individuals with neurofibromatosis type 1 (NF1). The update expands the trial population but reports no clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
AZTR0.35
More News
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share